We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-13.94%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.49B
AUM Growth
-$764M
Cap. Flow
-$255M
Cap. Flow %
-10.24%
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
17

Top Buys

1
CLVS
Clovis Oncology, Inc.
CLVS
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M
3
MDT icon
Medtronic
MDT
+$39.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.5M
5
EPZM
Epizyme, Inc
EPZM
+$33.5M

Top Sells

1
WCG
Wellcare Health Plans, Inc.
WCG
+$50M
2
BLUE
bluebird bio
BLUE
+$36.8M
3
ELV icon
Elevance Health
ELV
+$32.6M
4
CNC icon
Centene
CNC
+$32.1M
5
NUVA
NuVasive, Inc.
NUVA
+$31.2M

Sector Composition

1 Healthcare 95.6%
2 Financials 1.69%
3 Energy 0.02%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
51
AtriCure
ATRC
$1.81B
$9.18M 0.37%
+300,000
New +$9.35M
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
$9.16M 0.37%
3,564,950
-26,100
-0.7% -$87.4K
AXNX
53
DELISTED
Axonics, Inc. Common Stock
AXNX
$9.07M 0.36%
+600,000
New +$8.93M
GBT
54
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.88M 0.28%
+167,600
New +$6.28M
KRYS icon
55
Krystal Biotech
KRYS
$10.1B
$6.75M 0.27%
+325,000
New +$6.8M
ODT
56
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.43M 0.26%
456,951
-148,349
-25% -$2.31M
NVTA
57
DELISTED
Invitae Corporation
NVTA
$5.81M 0.23%
525,375
– –
ONC
58
BeOne Medicines Ltd
ONC
$32.2B
$5.67M 0.23%
40,400
+100
+0.2% +$13.3K
ESTA icon
59
Establishment Labs
ESTA
$2.7B
$3.9M 0.16%
142,167
-7,833
-5% -$191K
OVID icon
60
Ovid Therapeutics
OVID
$455M
$1.78M 0.07%
737,550
+7,400
+1% +$33.8K
ARVN icon
61
Arvinas
ARVN
$520M
$1.75M 0.07%
136,300
– –
JNCE
62
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$864K 0.03%
256,473
-168,942
-40% -$789K
ELGX
63
DELISTED
Endologix Inc
ELGX
$575K 0.02%
80,048
-998
-1% -$11.1K
LHCG
64
DELISTED
LHC Group LLC
LHCG
$394K 0.02%
4,200
-213,280
-98% -$20.4M
MYOK
65
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$387K 0.02%
7,930
+760
+11% +$41.8K
RGEN icon
66
Repligen
RGEN
$8.4B
$317K 0.01%
6,020
-13,980
-70% -$820K
VCEL icon
67
Vericel Corp
VCEL
$2.45B
$291K 0.01%
16,720
-3,280
-16% -$49.1K
SAGE
68
DELISTED
Sage Therapeutics
SAGE
$283K 0.01%
2,950
+780
+36% +$89.3K
GWPH
69
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$275K 0.01%
+2,820
New +$370K
IRTC icon
70
iRhythm Holdings
IRTC
$3.75B
$272K 0.01%
+3,910
New +$296K
FLXN
71
DELISTED
Flexion Therapeutics, Inc.
FLXN
$150K 0.01%
13,260
– –
VKTX icon
72
Viking Therapeutics
VKTX
$4.19B
$124K 0.01%
16,260
-13,740
-46% -$164K
ACRS icon
73
Aclaris Therapeutics
ACRS
$753M
$84K ﹤0.01%
11,320
– –
ADVM
74
DELISTED
Adverum Biotechnologies
ADVM
$70K ﹤0.01%
2,224
– –
SBBP
75
DELISTED
Strongbridge Biopharma plc.
SBBP
$56K ﹤0.01%
+12,500
New +$61K
1 2
3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q4 2018 Portfolio in Review

As of Q4 2018, Redmile Group held 96 positions worth $2.49B, down 24% from $3.25B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $255M in Q4 2018, closing 17 positions and reducing 38 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $50M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Energy.

Against the trend, Redmile Group opened a new position in Bristol-Myers Squibb worth $44.4M.

  • Redmile Group's largest Q4 2018 buy was Bristol-Myers Squibb: 854,700 shares worth $44.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2018, an estimated $46.6M increase.
  • Redmile Group's biggest Q4 2018 reduction was Elevance Health, cutting an estimated $32.6M.
  • Redmile Group fully exited Wellcare Health Plans, Inc. in Q4 2018, selling an estimated $50M.
  • Redmile Group's ten largest holdings make up 46% of its $2.49B portfolio in Q4 2018.
  • Redmile Group opened 13 new positions and closed 17 in Q4 2018.
  • Redmile Group's portfolio value fell 24% quarter-over-quarter to $2.49B.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.